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While the methodological principle of
‘blinding’ for minimising bias in randomised
controlled trials (RCT) is widely debated
and accepted, rarely is this depth of thinking
applied to its correct handling with respect
to design, reporting and analysis. Beyond
the general comprehension of the deﬁnition
of the word, the practical aspects of estab-
lishing blinding in investigator-initiated
pharmacological trials are often grossly
underestimated,1 and very much an after-
thought. The resulting inadequacy can
lead to trial delayed and increased costs,1
and can also potentially place the entire trial
at risk.
It is worth nothing that reporting of
blinding methodology is often absent or
of low quality in published articles of
RCTs.2 3 Thus, in such context, when
these fundamental details of trial design
are inadequately reported,2 3 it becomes
easier to see why it should be of no sur-
prise that there are, equally, very few pub-
lished commentaries addressing the
challenges of blinding that those embark-
ing on pharmacological trials face. So, it
would seem that little is available, at least
in biomedical literature, to guide investi-
gators on this particular methodological
aspect. A review of RCTs published over
15 years in this journal identiﬁed only
176 RCTs in children involving pharma-
ceutical interventions4; the authors sug-
gested that difﬁculties in obtaining
adequate placebos without the collabor-
ation of pharmaceutical companies may
have contributed to the low number.4 Our
experience over the years has also high-
lighted, among investigators, a deﬁciency
in the awareness of how pharmaceutical
ramiﬁcation can constrain trial design and
its validity.5 6 There is no denying that the
science underpinning blinding is very
much pharmaceutical based, and may be
technical at times, but part of this paucity
of knowledge is undoubtedly due to a
certain lack of recognition for the
pharmaceutical properties of a medicine.
This article, written with clinicians in
mind, presents a discussion on the prac-
tical considerations for blinding in paedi-
atric pharmacological trials, with the aim
to facilitate paediatricians in improving
the success and timely delivery of blinded
RCTs in children. Furthermore, this
article aims to encourage detailed disclos-
ure of blinding methodology in clinical
trial reporting.
BLINDING
Blinding in clinical trials refers to the
process of withholding information about
the assigned treatment from speciﬁc groups
of individuals. The ﬁrst blinded experiment
was conducted by Benjamin Franklin who
literally blindfolded participants to shield
them from knowledge in their assessments
of the therapeutic claims made for applying
mesmerism. Quite understandably, the use
of blindfolds is less favourable today.
Instead, identical-appearing treatments, be
it matching placebo or masked active com-
parator, are important tools in modern-day
pharmacological research.
When performed correctly, blinding is
intended to minimise the occurrence of
conscious and unconscious bias in the
conduct and interpretation of a trial until
all such opportunities for bias have
passed. The biases associated with prior
knowledge of treatment assignment are
well known, and the beneﬁts of blinding
have been presented elsewhere3 7 Indeed,
it is acknowledged that the relevance of
blinding will vary according to the clinical
trial context. In general, blinding of parti-
cipants, healthcare providers and outcome
assessors is considered important in
explanatory trials, where the primary
focus is to determine the efﬁcacy of an
intervention under ideal circumstances.8
By contrast, in pragmatic trials, as in the
real-world delivery of care, blinding of
participants and healthcare providers are
sometimes considered not necessary, so as
to render the ﬁndings more applicable to
usual care setting.8–10 Blinding is also par-
ticularly important when outcome
measures involve some subjectivity, and
becomes less so to reduce observer bias
for objective criteria.7 However, even
then, the lack of participant or healthcare
provider blinding can lead to other pro-
blems, such as differential attrition and
cointervention bias, which can likewise
inﬂuence the assessment of clinical trial
outcomes.7 10
BLINDING WITH PLACEBOS
The use of placebo in RCTs would appear
as a seemingly simple experimental
scheme. Such perception is so deeply
embedded that we often implicitly accept
clinical trial reporting with rather loose
descriptions of blinding procedures as
adequate indication for the success of
blinding.2 3 Rarely do we ask ourselves
any questions concerning the placebo, nor
do we think much, if at all, about the
work involved in producing them. The
fact is that the seemingly simple concept
does not necessarily hold true for obtain-
ing placebo supply. One cannot just pur-
chase matching placebo in an
‘off-the-shelf ’ manner; its provision needs
to be speciﬁc to each trial and the chal-
lenge is in the word ‘matching’. To
achieve its purpose, one must ensure the
placebo matches the sensory speciﬁcations
to that of the medicine under test. The
ability to maintain blindness throughout
the complete clinical trial must focus on
the visual aspects of the product, and
should also take into consideration the
other human senses. The relative import-
ance of these speciﬁcations will very much
depend on the route of administration
and the dosage form concerned; this may
include: shape, size, colour, texture,
weight, taste, smell11 and not merely a
‘sugar pill’.
An appropriate source for supply would
be the original manufacturer of the medi-
cine. After all, they would have manufac-
tured placebo for their own marketing
authorisation trials, and have all the
required technical data on the manufactur-
ing and analytical methods to support clin-
ical trial application. However, for many
pharmaceutical companies, the little incen-
tive to manufacture placebos on the com-
paratively limited quantity required by
most clinical trials is often disappointing
to the independent researchers.1 12 13
Even if one is fortunate enough to have
agreed a supply, commercial inﬂuence over
protocol design, trial results and publica-
tion can be somewhat disheartening.12 14
Short of compromising the study design
with an unblinded trial, an alternative
approach is to have the matching placebo
manufactured elsewhere. While it would
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be logical to use the same ingredients
(excipients) in the placebo formulation as
those in its active counterpart (without
the active drug), such approach does not
always guarantee a satisfactory level of
blinding. First, blinding is particularly
challenging where the actual drug itself
has a characteristic taste or colour, neces-
sitating the testing and addition of new
excipients to the placebo formulation in
order to achieve sensory equivalent.15 16
Second, and rather more problematically,
is when such addition is unsatisfactory; in
these circumstances, it may be necessary
to reformulate the active treatment from
its licensed form (eg, the addition of a
new excipient to mask the taste of the
active drug), to what is in effect manufac-
turing of a new product. The decision to
adopt such blinding strategy should, of
course, never be taken lightly.
To allow for variable dose delivery as a
result of age/weight/surface area-based
dosing, and to facilitate ease of adminis-
tration, liquid oral dosage form is often
required in the treatment of children,
making blinding liquid formulation a
more frequent issue in paediatric setting.
Compared with tablets and capsules, the
sensory characteristics of taste and smell
are more pronounced, yet, challenging to
match. Even simple ﬂavourings, such as
strawberry ﬂavour, can vary in taste
depending on the manufacturer, and thus
requiring the need to perform taste assess-
ment studies. There is also the additional
physical attribute of viscosity which one
must consider. Hence, some degree of for-
mulation development work is almost
always needed in developing a placebo
liquid formulation.
Likewise, for placebos intended for
topical use, the property of pH deserves
particular attention; the differences in pH
between the two products may lead to
local irritation in one group only, and
therefore distinct side-effects proﬁle will
effectively unblind the treatment arm and
biased assessments of endpoints may
result.
Even if developing the placebo formula-
tion was straightforward, difﬁculties can
arise with uniquely shaped tablets or pro-
ducts with speciﬁc markings,1 where the
complexity of matching these shapes and
proprietary designs may require specia-
lised equipment. The challenge is not
simply a matter of cost relating to the
equipment purchase, but also the fact that
the installation of new equipment will
necessitate a lengthy programme of quali-
ﬁcation and validation work. Less obvi-
ously, perhaps, is the possible issue of
infringement on trademark law. As far as
copying goes, certain imprints or mark-
ings on tablets are registered trademarks,
and therefore exclusive rights are
bestowed upon the trademark owner, the
drug’s original manufacturer.
Consequently, third-party placebo manu-
facturing is not always possible.
BLINDING OF ACTIVE COMPARATORS
To many, over-encapsulation may appear
to be the ubiquitous solution to blinding
solid oral formulations, and indeed, such
a technique can be very effective. As the
term implies, over-encapsulation is basic-
ally hiding a tablet or capsule inside an
opaque capsule shell (often involving the
addition of a backﬁlled excipient to
prevent rattling), so that the contents are
concealed, producing products that are
visually identical. This method of blinding
eliminates the need for matching placebo
manufacturing, and is particularly useful
for active-controlled trials requiring com-
parator blinding. However, over-
encapsulation increases the size of the ori-
ginal dosage form, potentially making
administration more difﬁcult. The use of
such blinding method in a trial involving
the younger subset of the paediatric popu-
lation may therefore be problematic.
More importantly, one must remember
that a medicine is made up of ingredients
other than the active drug, and the effects
of the drug are, in part, dependent on the
properties and proportions of these other
components. Thus, it is the dosage form
in which the active drug is administered
that determines the overall therapeutic
efﬁcacy and safety of the drug. As over-
encapsulation brings new ingredients into
the question, and effectively creating a
new dosage form, demonstrating equiva-
lence between the encapsulated and ori-
ginal products becomes a prerequisite for
ensuring study result integrity.9 17
Alternatively, blinding of two substan-
tially different looking treatments may be
achieved by bespoke manufacturing both
treatments from their respective active
pharmaceutical ingredients into either
capsules or tablets.9 With this method, the
visual appearance of the two treatments
can be controlled from the outset, but
again, there remains the question of
equivalent bioavailability, as well as the
operational challenges in manufacturing
two formulations within the resource con-
straints imposed by ﬁnite research
funding.
Suppose we now have a blinded active-
controlled comparator trial of two com-
mercially available liquid formulations.
This clearly differs from the case with
tablets or capsules, whereby over-
encapsulation can potentially provide the
solution to the problem. A sensible
approach would be to consider the double-
dummy blinding strategy. With this
approach, the comparator doesn’t need to
match the test product. Instead, a placebo
matching the test product and a second
placebo matching the comparator product
are used. Although such a study design
may be more pragmatic, it does have some
drawbacks. On the one hand, there are
considerable technical difﬁculties, as dis-
cussed above, with manufacturing placebo
for liquid formulation. As two matching
placebos are now needed, this would
require additional research expense and
time. On the other hand, the double-
dummy design requires participants to
take two study medications; in cases where
the medicines concerned require multiple
daily doses, this raises the question of the
potential risk of non-compliance.
For infusion therapy, blinding can trans-
late into a somewhat cumbersome setup.
Some researchers have used opaque
tubing and the covering of infusion bag
with plastic sleeve to mask its content.18
We question the robustness of such blind-
ing method, where we believe that the
risk of unblinding through routine hand-
ling of the infusion administration set is
substantial. Moreover, when visual inspec-
tion of the infusion bag and its adminis-
tration set is a standard safety precaution
measure for nursing staff when adminis-
tering infusion therapy, the feasibility and
acceptability of such blinding technique
may be limited in practice to allow the
trial to be delivered successfully. In these
situations, researchers must acknowledge
this reality, accepting the unblinded status
of those administering the treatment. The
use of unblinded personnel, though
imperfect, does not necessarily lead to an
unblinded trial. By limiting the activity of
the unblinded personnel to that of treat-
ment administration only, it remains pos-
sible to blind other key trial personnel,
and not limited to only outcome assessors.
Nonetheless, researchers should anticipate
that maintaining blinding by such method-
ology will be labour intensive, and that
guarding against inappropriate unblinding
must be a high priority.
THE ‘INERT’ INGREDIENTS
There is certainly a need to consider the
suitability of an excipient for use in
placebo manufacturing or in comparator
products masking with respect to its
safety. Indeed, the basic considerations
will not be different to that of marketed
medicines, with even greater scrutiny in a
paediatric setting in view of the potential
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risk of more pronounced safety implica-
tions. Risk assessments of excipients used
in the context of blinding still apply, and
on the whole, those with identiﬁed risks
relevant to the target age groups con-
cerned should be avoided, as their use
cannot be reasonably justiﬁed for the sole
purpose of blinding.
Moreover, the use of any excipient
requires additional concern considering
the fact that excipients have proved to be
anything but inert,19 and these possible
speciﬁc effects represent a potential con-
founding factor that may be vital to inter-
preting the study results. The
appropriateness of using nebulised saline
as a placebo in bronchodilator studies
assessing symptoms relief involving
patients with respiratory problem has been
questioned.20 Similarly, placebos of corn
oil or olive oil in cardiac trials have raised
doubts.21 The question of under what cir-
cumstances it is suitable, if ever, to use a
particular excipient will depend on our
current knowledge, and this may change
with advances in scientiﬁc research. With
this in mind, the disclosure of placebo
composition in clinical trial reporting, at
least in cases where there are differences in
excipients between the two experimental
arms, becomes ever so important should
further excipient data emerge at a later
date.
PACKAGING
There is little merit in creating a matching
placebo or masking a comparator, when
for example, the active is contained in a
silver aluminium blister strip whereas
white plastic blister has been used to
package the placebo. The requirement for
matching must go beyond the actual pro-
ducts and extends to all associated pack-
aging and labelling. On occasions, the
need for repackaging of medicines cannot
be avoided and its implications must be
reviewed at the outset.
The need for repackaging may not
always be apparent at the time when the
pharmaceutical company agreed to
provide the clinical trial supply. Amidst
the excitement of agreeing the supply, one
must request for detailed information on
the packaging to assess its suitability for
the trial. Medicines provided in its com-
mercial form are often packaged in a
branded manner and as such cannot be
copied. Other than the additional time
and cost for depackaging and repackaging
activities, the impact of these undertakings
on product integrity and stability needs to
be reviewed. The original manufacturer’s
stability data supports only the medicine
in its original packaging, and unless
equivalent or more protective packaging is
used, which itself may be difﬁcult to
determine, a reduction in the medicine
expiry date cannot be avoided. Although
a reduction in the expiry date from 36 to
24 months may have little bearing for a
trial of 12 months duration, the effect of
such reduction on a 30 months trial can
be very costly.
REPORTING
In light of the challenges discussed above,
it is surprising that such topics have had so
little mention in most commentaries. Then
again, despite being included in the
minimum set of recommendations in the
Consolidated Standards of Reporting
Trials (CONSORT) statement,22 the
reporting of the blinding status of key trial
persons, and of the blinding procedures, is
still frequently incomplete or missing.23
Most of all, when the reporting of basic
information such as details on the dosage
form of medicine is frequently absent in
published articles,24 it does beg the ques-
tion as to whether readers have simply
assumed that blinding has been appropri-
ately controlled for biases without actually
knowing how well it worked or even if it
worked at all.
While it would be inappropriate to
assume inadequate blinding merely on the
basis of inadequate reporting, equally, the
assumption of adequate blinding when
reporting is absent or inadequate cannot
be justiﬁed. If most researchers supposedly
comprehend the importance of establish-
ing blinding, then it is only expected that
they would also want to know whether
blinding was executed successfully. We
recognised that there are methodological
uncertainties surrounding testing the
success of blinding,1 24 but nonetheless,
we support greater disclosure and trans-
parency in blinding methodology report-
ing in a manner that reﬂects
pharmaceutical considerations. There cer-
tainly should be explicit reporting on who
was blinded, with additional information
on the methods involved in introducing
and maintaining blinding.3 7 Where feas-
ible, we also strongly encourage the
conduct and reporting of pretrial evalu-
ation of the identity of the two compared
treatments.3 25
We recognised that blinding of all key
trial personnel is not always technically or
practically possible, and on occasion, the
cost of blinding is such that the trial is no
longer feasible even with generous
increase in funding. Do we then simply
disregard blinding? The issue is not
whether blinding should be disregarded,
but investigators need to carefully assess
how much bias might ensue owing to
absence of blinding, and to explore alter-
native methods of trial design to minimise
the risk of bias in the trial. More import-
antly, they should provide clear justiﬁca-
tions for their decisions, and report any
speculation on the effect of any factors
arising from the course of the trial which
may impact on the outcome measures.
Clinical trials, even when most personnel
are unblinded, can remain methodologic-
ally sound in terms of controlling selec-
tion bias through proper randomisation
and adequate allocation concealment.
However, we, like others, take the view
that it is almost always possible to ensure
that the outcome assessor in a trial is
blinded.3 We strongly encourage this
aspect of blinding to be implemented, and
if not done, the rationale should be
clearly reported.
DISCUSSION
The concept of blinding may appear rela-
tively simple, but in reality, substantial
practical difﬁculties can arise in construct-
ing apparently identical treatment. Just as
you would always discuss with an experi-
enced statistician when designing a trial,
for example, the need for stratiﬁcation in
randomisation or the population SD in
sample size determination, the same level
of detailed discussion is needed with
respect to blinding. Determining the most
appropriate blinding strategy is often
complex; as highlighted by the recurring
theme of this article, signiﬁcant timing
and cost is involved. As such, blinding
strategy deserves particular attention from
investigators at the earliest stages of trial
planning, preferably before seeking
funding.
We recommend that investigators take a
balance approach to blinding strategy with
consideration of a risk-based assessment
of clinical, pharmaceutical, logistical and
resource factors. Engaging with experi-
enced individuals, such as research phar-
macists, and initiating dialogue on
formulations and blinding early in the
trial design phase can help to avoid
unworkable blinding options, as well as to
ensure the work required for blinding is
timely delivered.1 Considering the chal-
lenges discussed, we further recommend
funding bodies to consider making
pharmaceutical expert review a condition
of public funding for pharmacological
RCTs. At the very least, editors of bio-
medical journals should mandate explicit
blinding reporting be part of articles con-
sidered for publication. It is only through
better reporting and critical analysis that
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we can build our body of knowledge on
blinding methodology.
An article of this size cannot possibly
address the different approaches to blind
different dosage forms or the regulatory
framework governing pharmaceutical
manufacturing. Rather, the aim is to intro-
duce researchers to some of the key
pharmaceutical concepts and associated
vocabularies. Blinding should, under no
circumstances, be seen as a means to an
end, when in fact, pharmaceutical proper-
ties of the medicine should drive the
choice of blinding method which, in part,
will inform the design and operational
delivery of the trial.
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